1. 2002
2. Cyhoeddwyd

   Economic evaluation during early (phase II) trials

   Hughes, D. & Hughes, D. A., 1 Tach 2002.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   Impact of non-compliance on the cost-effectiveness of pharmaceuticals

   Hughes, D. & Hughes, D. A., 1 Tach 2002.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Patient compliance and pharmacoeconomics

   Hughes, D. & Hughes, D. A., 1 Tach 2002.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. Cyhoeddwyd

   The population pharmacokinetics of lapdap

   Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Tach 2002.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   Economic impact of poor compliance with pharmaceuticals.

   Hughes, D. & Hughes, D. A., 1 Awst 2002, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, t. 327-335

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

   Hughes, D. & Hughes, D. A., 1 Mai 2002.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

8. Cyhoeddwyd

   Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

   Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

9. Cyhoeddwyd

   Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

   Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

10. 2001
11. Cyhoeddwyd

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Tach 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

12. Cyhoeddwyd

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Hyd 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

13. Cyhoeddwyd

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Hyd 2001, Yn: Health Economics. 10, 7, t. 601-615

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

14. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Medi 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

16. Cyhoeddwyd

    A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

17. Cyhoeddwyd

    Accounting for non-compliance in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 12, t. 1185-1197

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

18. Cyhoeddwyd

    Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 11, t. 1069-1077

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

19. Cyhoeddwyd

    Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

    Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

20. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

21. 2000
22. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Tach 2000.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    Pragmatic trials - design features and implications for clinical decision making

    Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Awst 2000.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2000, Yn: Value in Health. 3, 5, t. 373

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid